Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours-Reference-Cited by-同舟云学术

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours

Published:2019-02-06 Issue:5 Volume:120 Page:527-536
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Martin Valentina,Chiriaco Cristina,Modica Chiara,Acquadro Anna,Cortese Marco,Galimi Francesco,Perera Timothy,Gammaitoni Loretta,Aglietta Massimo,Comoglio Paolo M.,Vigna Elisa,Sangiolo Dario

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-018-0315-3.pdf

Reference62 articles.

1. Dong, H., Zhu, G., Tamada, K. & Chen, L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5, 1365–1369 (1999).

2. Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027–1034 (2000).

3. Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793–800 (2002).

4. Zou, W. & Chen, L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8, 467–477 (2008).

5. Chen, L. & Han, X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J. Clin. Invest. 125, 3384–3391 (2015).

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modulation of MHC expression by interferon-gamma and its influence on PBMC-mediated cytotoxicity in canine mast cell tumour cells;Scientific Reports;2024-08-01

2. Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma;Cancer Research Communications;2024-07-01

3. MET Oncogene Targeting for Cancer Immunotherapy;International Journal of Molecular Sciences;2024-06-01

4. MET-Targeting Anticancer Drugs—De Novo Design and Identification by Drug Repurposing;Drugs and Drug Candidates;2023-07-18

5. Targeting MET: Discovery of Small Molecule Inhibitors as Non-Small Cell Lung Cancer Therapy;Journal of Medicinal Chemistry;2023-06-01